{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-000247","form_type":"8-K","ticker":"CTXR","cik":"0001506251","company_name":"Citius Pharmaceuticals, Inc.","filed_at":"2024-01-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.375676+00:00","generated_at":"2026-06-07T05:14:48.209511+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Citius Pharma FY2023 net loss $32.5M; Mino-Lok Phase 3 enrollment done, topline Q2 2024","bullets":["Net loss $32.5M ($0.22/share) for FY ended Sep 30, 2023; cash $26.5M, runway through Aug 2024.","Mino-Lok Phase 3 completed (241 patients, 109 events); topline results expected Q2 2024.","LYMPHIR BLA resubmission on track for early 2024 after July 2023 CRL; PDUFA later in 2024.","Halo-Lido Phase 2b completed; end-of-Phase 2 meeting with FDA planned early 2024.","Oncology subsidiary to merge with TenX Keane Acquisition (TENKU) to form publicly listed Citius Oncology."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-000247","json":"https://secwatch.observer/filing/0001213900-24-000247.json","markdown":"https://secwatch.observer/filing/0001213900-24-000247.md","text":"https://secwatch.observer/filing/0001213900-24-000247.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1506251/000121390024000247/0001213900-24-000247-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1506251/000121390024000247/ea190916-8k_citius.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T05:14:48.209511+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2482e38b01721632362f6b5cceb16763913f785a","claim":"Citius Pharmaceuticals, Inc. reported fiscal full year ended September 30, 2023 results: net income Net loss was $32.5 million, or ($0.22) per share, EPS ($0.22) per share.","evidence_excerpt":"Net loss was $32.5 million, or ($0.22) per share for the full year ended September 30, 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1506251/000121390024000247/0001213900-24-000247-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fiscal full year ended September 30, 2023"},{"label":"Net income","value":"Net loss was $32.5 million, or ($0.22) per share"},{"label":"EPS","value":"($0.22) per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}